Key Highlights
- Third-quarter 2026 net loss was USD 50.7 million, or USD 1.23 per share.
- Research and development expenses were USD 27.5 million, against USD 25.0 million.
- Cash, cash equivalents and marketable securities were approximately USD 324.4 million.
- The Galera Merger and Concurrent PIPE Financing closed on August 3, 2026.
Obsidian Therapeutics (NASDAQ:OBX) reported a third-quarter 2026 net loss of USD 50.7 million, or USD 1.23 per share, against an estimate of a loss of USD 0.52 per share, in its Quarterly Report on Form 10-Q. The clinical-stage company reported no revenue. Its lead product candidate, amsokigene autoleucel, formerly OBX-115, is a genetically engineered, autologous TIL cell therapy.
Quarterly Results
Research and development expenses were USD 27.5 million for the three months ended September 30, 2026, against USD 25.0 million a year earlier. The filing attributes the USD 2.5 million increase primarily to USD 1.3 million of higher personnel-related costs, including stock-based compensation, and a USD 1.0 million increase in clinical and Manufacturing costs from the advancement of its clinical studies, including increased patient enrollment and site activities.
General and administrative expenses were USD 10.3 million, against USD 4.6 million. The USD 5.7 million increase was primarily due to a USD 2.5 million increase in compensation and related costs, including stock-based compensation. Other income, net, was USD 2.3 million, against USD 1.2 million.
Net loss for the quarter was USD 50.7 million, against USD 28.5 million in the prior-year period. Weighted-average common shares outstanding were 41,029,574, against 1,927,814. For the nine months, the net loss was USD 96.2 million, or USD 6.19 per share, against USD 80.4 million, or USD 41.70 per share.
Merger and Concurrent PIPE Financing
On April 14, 2026, Legacy Obsidian, Galera Therapeutics, Inc. and Gazelle Parent, Inc. entered into an Agreement and Plan of Merger. On August 3, 2026, the transactions contemplated by the merger agreement closed, and Legacy Obsidian and Legacy Galera each became wholly owned subsidiaries of the parent company. The merger was accounted for as a reverse asset acquisition.
In the Concurrent PIPE Financing, the company issued 29,164,045 shares of common stock, with proceeds of USD 350.0 million and issuance costs of USD 19.5 million. It also issued 777,236 shares and warrants to Legacy Galera securityholders. The filing refers to obligations under a contingent value rights agreement and to resales of shares registered on a Form S-1 resale registration statement.
Clinical Programs and Balance Sheet
The filing describes amsoki-cel as currently in a Phase 2 clinical trial for advanced melanoma and a Phase 1 clinical trial for non-small cell lung cancer.
As of September 30, 2026, the company had cash, cash equivalents and marketable securities of approximately USD 324.4 million, consisting of approximately USD 66.5 million of cash and cash equivalents, USD 148.4 million of current marketable securities and USD 109.4 million of long-term marketable securities. This compares with USD 80.5 million at December 31, 2025. A stockholders' Deficit of USD 266.0 million at the end of 2025 changed to stockholders' Equity of approximately USD 320.6 million, which the filing attributes primarily to the Concurrent PIPE Financing and the mergers, partly offset by cash used in operating activities.
Net cash provided by financing activities for the nine months was USD 331.4 million, and net cash used in investing activities was USD 221.2 million. Conversion of preferred stock into common stock was USD 338.0 million. There were 61,774,046 shares of common stock outstanding at September 30, 2026, and the accumulated deficit was USD 392.1 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...